Navigation Links
Frost & Sullivan Recognized Top Industry Innovators
Date:4/23/2013

t Corporation-Microsoft PlayReady - 2012 Global Content Protection Enabling Technology Award

Novus International - 2012 North American Animal Feed Ingredients Product Differentiation Excellence Award

Ooyala - 2012 Global Online Video Platforms Customer Value Enhancement Award

OpenText - 2013 Global Enterprise Digital Media Company of the Year Award

Pharmaco-Kinesis Corporation - 2013 Global Biosensors New Product Innovation Award

POWERVAR - 2013 Global Healthcare Uninterruptible Power Supplies Competitive Strategy Leadership Award

Proofpoint, Inc. - 2012 North American Email Content Security Product Differentiation Excellence Award

QUA Group - 2013 North American Industrial Water and Wastewater Treatment Technology New Product Innovation Award

RWL Water Group - 2013 North American Water and Wastewater Treatment Excellence in Mergers & Acquisition Strategy Award

ShinewayTech - 2012 Global Fiber Optic Test Equipment Price Performance Value Leadership Award

SIMCO Electronics - 2013 North American Calibration and Repair Service Leadership Award

Sprint -
2012 North American Mobile Communications and Collaboration Customer Value Enhancement Award

2012 North American Mobile & Wireless Green Excellence Award

2013 North American Automotive Usage Based Insurance Customer Value Enhancement Award

TEOCO - 2012 Stratecast Global Communications Service Provider Financial Assurance Product Line Strategy Award

The Sente Group - 2013 North American Test Asset Management Solutions for Aerospace & Defense Customer Value Enhancement Award

TomTom Business Solutions - 2012 North American Commercial Vehicle Telematics Customer Value Enhancement Award

Trustwave -
2012 Global Web Content Filtering Products Product Differentiation Excellence Award

2012 North American Managed Security Service Providers Growth Leadership Award

Vidtel - 20
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
3. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
4. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
5. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
6. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
7. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
8. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
9. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
10. Electronic Medical Records Progress from an Enterprise-Centric Solution to a Customer-Specific Application, Finds Frost & Sullivan
11. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Shire plc (LSE: SHP, Nasdaq: ... a study showing that coadministration of the ADHD medication VYVANSE(R) ... OTC(R) 40 mg (20 mg X 2), did not alter ... d -amphetamine to be reached in the subjects evaluated. ...
... trials begin enrollment in May 2009; Reinforces Lilly,s commitment ... 21 Eli Lilly and Company (NYSE: ... this month in two separate but identical Phase III ... an anti-amyloid beta monoclonal antibody being investigated as a ...
Cached Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 2Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 3Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 4Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 5
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... Components Corporation (ICC), an established global leader in ... a new series of high-efficiency AC-DC external power ... devices. Marketed under the Elpac Power Systems brand, ... company,s rapidly expanding portfolio of high-efficiency, high-reliability power ...
... Now Have Access to Low-Price Generic Options, Helping Consumers ... Stores Inc. (WMT) today announced its list of up ... will now be accessible to physicians using an Epocrates ... device. Physicians will now be better equipped to ...
... in Light of Economic Downturn, According to New ... HealthLeaders-InterStudy, a leading provider of managed care ... efforts in Louisiana and Rhode Island will likely ... downturn, particularly as Medicaid populations grow.According to the ...
... MOUNTAIN VIEW, Calif., Feb. 19 Based on its ... Frost & Sullivan recognizes Horphag Research Ltd. with the ... of the Year Award. The award acknowledges the company,s ... 40 years, aimed at validating the health benefits of ...
... Inc. (Nasdaq: CADX ) announced today that it ... shares of the Company,s common stock at a price of ... approximately 6 million additional shares of the Company,s common stock, ... of $7.84 per share, for aggregate gross proceeds of approximately ...
... - Defyrus Inc. today announced the signing an ... by the United Kingdom,s Defence Science and Technology ... Dstl,s commercialization company. These patents form the intellectual ... programs. Defyrus and Ploughshare Innovation Ltd plan to ...
Cached Medicine News:Health News:Elpac Power System 150-Watt Commercial External Power Supply Features Industry-Leading Efficiency and Power Density 2Health News:Wal-Mart's $4 Generic Prescription Drug List Added to Epocrates' Drug Reference Application 2Health News:Wal-Mart's $4 Generic Prescription Drug List Added to Epocrates' Drug Reference Application 3Health News:Medicaid Reform Efforts Underway in Louisiana and Rhode Island 2Health News:Medicaid Reform Efforts Underway in Louisiana and Rhode Island 3Health News:Frost & Sullivan Recognizes Horphag's Pioneering R&D Efforts in Health Ingredients 2Health News:Frost & Sullivan Recognizes Horphag's Pioneering R&D Efforts in Health Ingredients 3Health News:Frost & Sullivan Recognizes Horphag's Pioneering R&D Efforts in Health Ingredients 4Health News:Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock 2Health News:Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock 3Health News:Vaccine patent portfolio licensed from UK Ministry of Defence 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: